Our new San Diego location is currently under development, and will include more than 63,000 square feet of mixed-use space optimized for both laboratory operations and research and development. The office will consolidate the company’s two San Diego locations under one roof in Torrey Pines, the center of the city’s life science cluster.

The new laboratory space will help to expand testing capacity of the company’s recently FDA-approved FoundationOne Liquid CDx liquid biopsy test. Additionally, with Foundation Medicine’s acquisition of Lexent Bio* in June, the new space will allow for increased research and development of low-pass whole genome sequencing and DNA methylation analysis. The site hosts the following teams - Laboratory Operations, Facilities, Technology, TOCR, Research and Development (Early Research and Assay Development), Medical, and Legal teams. Client Services and other teams will be there as well soon.

“This state-of-the-art facility provides the opportunity to further expand our R&D and laboratory operations and supports our focus on advancing personalized medicine for patients,” said Foundation Medicine’s Chief Scientific Officer Priti Hegde, Ph.D. “The San Diego region is home to more than 1,200 life sciences companies—we’re excited to embed ourselves in this burgeoning community, deepen our local partnerships and add this high-quality lab space to expand into new projects.”

Foundation Medicine’s labs in Cambridge; Research Triangle Park, North Carolina; and Penzberg, Germany will continue to analyze individual patients’ genomic profiles, using the company’s portfolio of genomic tests, to identify the molecular alterations in a patient's cancer and help physicians match them with relevant personalized treatment approaches, including targeted therapies, immunotherapies and clinical trial options.

*Our Acquisition of Lexent Bio, Inc.

In June of 2020, we completed the acquisition of Lexent Bio, Inc., a precision oncology company located in California, developing novel multiomics liquid biopsy platforms to advance cancer care. This acquisition will accelerate our research and development strategy and expand its existing liquid biopsy platforms to advance cancer care for patients. The technology developed by Lexent Bio complements our existing efforts and partnerships aimed at developing advanced diagnostics for physicians, as well as genomically evaluating disease progression and informing treatment decisions at earlier stages of disease. Read more here.